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Abstract
Background ATT RAC TION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with 
advanced gastric cancer treated with ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment 
beyond progression (TBP) with nivolumab have not been clarified.
Methods The 3-year follow-up data were collected. A subset analysis was performed to explore the efficacy of TBP by 
assessing postprogression survival (PPS) after the first event of disease progression.
Results Overall, 493 patients were randomized (2:1) to receive nivolumab (n = 330) or placebo (n = 163). With a median 
follow-up of 38.5 (range 36.1–47.5) months, OS of the nivolumab group was significantly longer compared to the placebo 
group (median 5.3 vs 4.1 months; 3-year survival rate, 5.6% vs 1.9%; hazard ratio [HR], 0.62 [95% confidence interval (CI) 
0.50–0.75], P < 0.0001). The median OS of responders (n = 32) who achieved complete response or partial response was 
26.7 months and the 3-year survival rate was 35.5% in the nivolumab group. Overall, 109 patients in the nivolumab group 
and 37 patients in the placebo group received TBP. PPS tended to be longer in the nivolumab group vs placebo group (median 
5.8 vs 4.5 months; HR [95% CI], 0.69 [0.47–1.01], P = 0.057). In contrast, PPS was similar between both treatment groups 
in non-TBP patients (median 2.3 vs 2.2 months; HR 0.90, P = 0.42).
Conclusions Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with 
nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the 
future.
Keywords ATT RAC TION-2 · Gastric or gastroesophageal junction cancer · Nivolumab · Long-term efficacy · Treatment 
beyond progression
Introduction
Immune checkpoint inhibitors (ICIs) are a new option for 
anticancer treatment [1]. The efficacy of ICIs was evalu-
ated initially in patients with previously treated [2] and then 
in untreated patients with metastatic melanoma without 
BRAF mutations [3], demonstrating improved overall sur-
vival (OS) in both populations. Subsequently, ICIs proved 
to be efficacious in several treatment lines for various cancer 
types, including lung cancer, renal cell carcinoma, and head 
and neck cancer [4–8].
ATT RAC TION-2 was the first phase 3 study that dem-
onstrated the efficacy and safety of nivolumab, a monoclo-
nal antibody that blocks programmed death-1 (PD-1), as 
a third- or later-line treatment for patients with advanced 
gastric/gastroesophageal junction (G/GEJ) cancer com-
pared with placebo [9]. In contrast, the JAVELIN Gastric 
300 study of avelumab, a monoclonal antibody against 
programmed death-ligand 1 (PD-L1), failed to show supe-
riority in OS compared with treatment of the physician’s 
choice [10]. While the two phase 3 trials of pembrolizumab 
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showed marginally negative results in the first- and second-
line setting for advanced G/GEJ cancer [11, 12], one of the 
two phase 3 trials of nivolumab showed an OS benefit of 
nivolumab in combination with standard chemotherapy ver-
sus chemotherapy alone in the first-line setting [13, 14]. It is 
speculated that the utility of ICIs may depend on the clini-
cal setting in relation to the cancer types, treatment lines, 
and combination therapy, and treatment strategy with ICIs 
should be optimized in each situation.
One of the distinctive characteristics of ICIs is their 
long-term efficacy, which was reported in melanoma and 
lung cancer [8, 15–18]. While there are no reports on the 
long-term efficacy of salvage-line chemotherapy with cyto-
toxic agents such as irinotecan and trifluridine–tipiracil 
(TAS-102) in patients with advanced G/GEJ cancer, pre-
vious reports have demonstrated the efficacy and safety 
of ICIs at the 2-year follow-up with nivolumab in the 
ATT RAC TION-2 study [19] and with pembrolizumab in 
the phase 2 KEYNOTE-059 study [20]. However, to date, 
no studies have reported the long-term efficacy of ICIs for 
advanced G/GEJ cancer. Another distinctive feature of ICIs 
is a phenomenon called pseudoprogression [21–25]. Treat-
ment with ICIs activates lymphocytes, which may accu-
mulate in the tumor, resulting in an apparent enlargement 
in the tumor size. Pseudoprogression is often difficult to 
distinguish from true tumor progression [26]. In this con-
text, continuous treatment beyond progression (TBP) may 
be important until true disease progression. Furthermore, 
it has been reported that some patients with melanoma, 
renal cell carcinoma, and lung cancer may receive clinical 
benefits from TBP with nivolumab [27–29]. Indeed, in the 
ATT RAC TION-2 study, after the first event of progressive 
disease (PD), TBP with nivolumab or placebo was permit-
ted at the investigator’s expectation of clinical benefit and 
the patient’s consent for continuing the protocol treatment 
beyond the first evidence of PD [19]. Thus, TBP might have 
influenced the overall results of the ATT RAC TION-2 study. 
The decision of selecting the next treatment at the first event 
of PD with nivolumab is clinically important, either TBP 
or a switch to other pharmacotherapies, in the salvage-line 
treatment of patients with advanced G/GEJ cancer. However, 
it is unclear whether TBP with nivolumab might have a sur-
vival benefit over placebo.
Here, we report the 3-year follow-up data of the 
ATT RAC TION-2 study and a subset analysis of postpro-
gression survival (PPS) after the first event of PD in all 
patients who received TBP in the nivolumab and placebo 




ATT RAC TION-2 was a randomized, double-blind, placebo-
controlled, phase 3 study conducted at 49 sites in Japan, 
South Korea, and Taiwan (NCT02267343). The detailed pro-
cedure of the ATT RAC TION-2 study has been published 
[9]. Briefly, eligible patients, who were aged ≥ 20 years, hav-
ing an Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 or 1, and unresectable advanced 
or recurrent G/GEJ cancer histologically confirmed to be 
adenocarcinoma refractory to or intolerant of ≥ 2 lines of 
standard chemotherapy, were randomized (2:1) to receive 
nivolumab or placebo [9].
Written informed consent was provided by all patients 
before enrollment and before TBP. The study was conducted 
in accordance with the Declaration of Helsinki and the Good 
Clinical Practice guidelines developed by the International 
Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use [9].
Procedures
The study treatment (intravenous infusion of nivolumab 
[3 mg/kg] or placebo every 2 weeks for 6 weeks [one cycle]) 
was continued until disease progression or the onset of tox-
icities requiring permanent treatment discontinuation. TBP 
was allowed for patients who met the following criteria 
at the first event of PD: expectation of clinical benefit, no 
rapid disease progression, tolerance to the study drug and 
preserved PS, no risk of interference from any intervention 
required to prevent serious complications due to disease 
progression with TBP, and provision of written informed 
consent for TBP [9].
Response was evaluated according to the Response Eval-
uation Criteria in Solid Tumors (RECIST) guidelines ver-
sion 1.1 [30] using computed tomography (CT) or magnetic 
resonance imaging (MRI) every cycle for the first 10 cycles 
and every two cycles thereafter until permanent discontinu-
ation of the study treatment due to any cause.
Analysis
The primary endpoint was OS. Secondary endpoints were 
progression-free survival (PFS), BOR (complete response 
[CR], partial response [PR], stable disease [SD], and PD), 
objective response rate (ORR; the proportion of patients 
with confirmed CR or PR), and duration of response (DOR). 
Additionally, a subanalysis of OS by BOR was conducted 
in this study. Treatment-related adverse events (TRAEs) of 
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special interest were also evaluated. Biomarkers including 
PD-L1 expression on tumor cells, tumor mutation burden 
(TMB), and microsatellite instability (MSI) were evaluated 
retrospectively.
PPS was calculated from the first event of PD to death 
from any cause, which was evaluated in all patients who 
received TBP and then in subpopulations according to the 
BOR and patterns of PD. The patterns of PD were classi-
fied as (1) increase in tumor size of existing target lesions 
by ≥ 20% without new lesions, (2) increase in tumor size by 
< 20% with new lesions, and (3) increase in tumor size by 
≥ 20% with new lesions. Duration of TBP was defined as the 
interval between the first event of PD and the last adminis-
tration of nivolumab or placebo. Additionally, PPS was also 
analyzed in patients not receiving TBP. Although there is 
no consensus for the definition of pseudoprogression with 
immune-oncology therapy, the change in tumor size after the 
first event of PD was assessed in all patients receiving TBP 
who had measurable lesions.
Statistics
The Kaplan–Meier (KM) method was used to estimate OS, 
PFS, and PPS, which were compared between the two treat-
ment groups using the stratified log-rank test with a one-
sided significance level of 0.025. Hazard ratio (HR; 95% 
confidence interval [CI]) was calculated using the stratified 
Cox proportional hazards model. A subgroup analysis of 
OS by PD-L1, TMB, and MSI status was performed with 
an unstratified Cox model, including HR and correspond-
ing 95% CIs, to examine the effect of treatment on OS. A 
spider plot was presented to evaluate the change in tumor 
size compared to the first event of PD among patients with 
measurable lesions and imaging data during TBP. All analy-
ses were performed using SAS versions 9.3 and 9.4 (SAS 
Institute, Inc., Cary, NC, USA).
Results
Patient disposition
Overall, 601 patients were enrolled, of whom 493 
(nivolumab 330, placebo 163) were randomized between 
November 4, 2014, and February 26, 2016. Baseline char-
acteristics were presented in the previous publication [9]. 
The data cutoff date for this 3-year follow-up was February 
17, 2019, with a median (range) follow-up period of 38.5 
(36.1–47.5) months in survivors. The response was assessed 
in 399 patients having measurable lesions (nivolumab 268, 
placebo 131). Among the 493 patients, the proportion of 
patients who received post-study treatment after permanent 
discontinuation of study treatment increased at the 3-year 
follow-up than in the previous report; 54.2% (179/330) of 
patients in the nivolumab group and 47.2% (77/163) in the 
placebo group (pharmacotherapy, 42.1% [139/330] and 35% 
[57/163]; surgery, 20.9% [69/330] and 17.2% [28/163]; radi-
otherapy, 8.8% [29/330] and 10.4% [17/163], respectively).
Efficacy
At the 3-year follow-up, the median OS (95% CI) in the 
nivolumab group (5.26 [4.60–6.37] months) was longer than 
that in the placebo group (4.14 [3.42–4.86] months). The 
risk of death was significantly lower in the nivolumab group 
than in the placebo group (HR [95% CI], 0.62 [0.50–0.75], 
P < 0.0001; Fig. 1a). The OS rate was consistently higher 
in the nivolumab group than in the placebo group through-
out the 3-year follow-up period. The 3-year OS rates were 
5.6 and 1.9% in the nivolumab group and placebo group, 
respectively.
Median PFS (95% CI) was 1.61 (1.54–2.30) months in 
the nivolumab group and 1.45 (1.45–1.54) months in the 
placebo group at the 3-year follow-up (Fig. 1b). The risk 
of disease progression was lower in the nivolumab group 
than in the placebo group (HR [95% CI], 0.60 [0.49–0.75], 
P < 0.0001; Fig. 1b). PFS rates were consistently higher in 
the nivolumab group than in the placebo group after approxi-
mately 2 months from treatment initiation. The 3-year PFS 
rates were 2.4 and 0% in the nivolumab group and placebo 
group, respectively (Fig. 1b).
Among the 192 patients whose tumor tissues were avail-
able for biomarker analysis, we found no difference in the 
efficacy of nivolumab compared with that of placebo in the 
subgroup analysis of OS categorized by biomarkers such as 
PD-L1, TMB, and MSI status (Online Resource Table 1).
The ORR and BOR were the same as reported at the 
2-year follow-up [19]. No patient in the placebo group 
achieved CR or PR. Among 32 patients with CR or PR 
(responders) in the nivolumab group, the median DOR 
(95% CI) was 10.12 (8.31–16.72) months, and the median 
(95% CI) OS was 26.68 (21.65–38.57) months, with 1-year, 
2-year, and 3-year OS rates of 87.1, 61.3, and 35.5%, respec-
tively (Fig. 2a). All three patients with CR on nivolumab 
treatment survived longer than 3 years. The OS in patients 
with SD as their BOR was numerically longer in the 
nivolumab group vs the placebo group (median OS 8.87 
vs 7.62 months; HR [95% CI], 0.75 [0.50–1.15], P = 0.18) 
(Fig. 2b). In patients with PD, the KM curves of the two 
treatment groups overlapped up to approximately 10 months 
before separating (median OS 3.84 vs 3.75 months; HR 
[95% CI], 0.83 [0.62–1.12], P = 0.21) (Fig. 2c).
The treatment duration of 3-year survivors receiving 
nivolumab and placebo is shown in Online Resource Fig. 1. 
In the nivolumab group, five of fifteen 3-year survivors 
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received nivolumab for 3 years. In the placebo group, two 
of three 3-year survivors received nivolumab as subsequent 
therapy (data not shown).
PPS in patients with or without TBP
Excluding the 38 and 29 patients who died before PD 
was determined, 20 and 17 patients in whom study drug 
administration was terminated due to apparent worsening 
of symptoms, 4 and 2 patients who could not be followed 
up after PD was determined, 3 and 2 patients in whom 
study drug administration was terminated due to adverse 
event(s), 4 and no patients in whom tumor shrinkage was 
persistent and continued at the 3-year follow-up, and 4 
and no patients who were not determined to have PD due 
to other reasons from the nivolumab and placebo groups, 
respectively, the TBP cohort comprised 38.9% (109/280) 
and 28% (37/132) of patients with confirmation of the first 
Fig. 1  OS (a) and PFS (b) after 
3 years of follow-up. Vertical 
marks on the curve indicate 
patients who were censored. CI 
confidence interval, HR hazard 
ratio, PFS progression-free 
survival, OS overall survival
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event of PD in the nivolumab and placebo groups (Online 
Resource Fig. 2). Patient demographics and baseline char-
acteristics were similar between the nivolumab and placebo 
groups both in the TBP and non-TBP patients (Table 1 and 
Online Resource Table 2). The median (range) duration of 
TBP was 1.12 (0–36.5) months and 1.08 (0–11.1) months 
in the nivolumab and placebo groups, respectively (Online 
Resource Table 3). The proportion of patients who received 
subsequent pharmacotherapy after nivolumab treatment 
among TBP patients (nivolumab group, 50.5% and placebo 
group, 54.1%; Table 1) was slightly higher than that among 
non-TBP patients (nivolumab group, 43.3% and placebo 
group, 34.7%; Online Resource Table  2). Among TBP 
patients, PPS tended to be longer in the nivolumab group 
(median PPS [95% CI], 5.75 [4.80–7.26] months) than in 
the placebo group (4.50 [2.83–6.37] months) with an HR 
(95% CI) of 0.69 (0.47–1.01) (P = 0.057) (Fig. 3). In con-
trast, among non-TBP patients, PPS was similar between the 
nivolumab and placebo groups (median PPS [95% CI], 2.27 
[2.00–2.60] months vs 2.23 [1.58–2.69] months, respec-
tively; HR [95% CI], 0.90 [0.70–1.16]; P = 0.42) (Online 
Resource Fig. 3).
Subanalysis of PPS by BOR in TBP patients
Among TBP patients, the median (95% CI) PPS was 12.48 
(10.05–21.78) months in patients achieving CR or PR in the 
nivolumab group (Fig. 4a) with a median (range) TBP dura-
tion of 4.75 (0.2–10.9) months (Online Resource Table 3). In 
patients with the BOR of SD in the nivolumab and placebo 
groups, the median (range) TBP duration was 1.12 (0–36.5) 
and 1.45 (0–11.1) months and the median (95% CI) PPS 
was 5.55 (4.17–8.41) months and 9.20 (6.24–14.92) months, 
respectively (HR [95% CI], 1.58 [0.67–3.71]) (Fig. 4b). In 
patients with the BOR of PD, the median TBP duration 
was 1.05 (0–11.0) and 1.08 (0–2.6) months, and PPS was 
similar until the median (95% CI) between the nivolumab 
group (4.24 [3.22–6.60] months) and the placebo group 
(3.78 [2.33–6.37] months); thereafter, the nivolumab group 
showed favorable long-term survival compared with the pla-
cebo group (HR [95% CI], 0.70 [0.42–1.18]) (Fig. 4c).
Change in tumor size in TBP patients
Among 109 patients receiving TBP with nivolumab, 89 
patients had measurable lesions and imaging data for evalu-
ation of the first event of PD. After excluding 17 patients 
who did not have imaging data and/or meet the criteria of 
PD defined in RECIST (increase in tumor size by ≥ 20% 
or appearance of new lesions) from these 89 patients, 72 
patients had measurable lesions and confirmation of the first 
event of PD by imaging. Their PD patterns were an increase 
in the tumor size of existing target lesions by ≥ 20% without 
new lesions in 24 patients, increase in tumor size by < 20% 
with new lesions in 31 patients, and increase in tumor size 
by ≥ 20% with new lesions in 17 patients. According to the 
BOR of these 72 patients, PD pattern due to appearance 
of new lesion with increase in tumor size by < 20% was 
observed in 8 (80%) of 10 patients with BOR of CR/PR, 9 
(50%) of 18 patients with SD, and 14 (32%) of 44 with PD 
(Online Resource Fig. 2).
Figure  5 shows a spider plot during TBP with 
nivolumab in these 72 patients categorized by PD pat-
terns—target lesion progression of ≥ 20% without a new 
lesion (n = 24, Fig. 5a), target lesion progression of < 20% 
Fig. 2  Subanalysis of OS by BOR among patients with CR + PR (a), 
SD (b), and PD (c). Vertical marks on the curve indicate patients who 
were censored. BOR best overall response, CI confidence interval, CR 
complete response, HR hazard ratio, OS overall survival, PD progres-
sive disease, PR partial response, SD stable disease
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Table 1  Patient demographics 
and baseline characteristics of 
patients receiving TBP
BOR best overall response, CR complete response, ECOG Eastern Cooperative Oncology Group, eCRF 
electronic case report form, NE not evaluated, PD progressive disease, PD-L1 programmed death-ligand 1, 
PR partial response, SD stable disease, TBP treatment beyond progression
Parameter (unit) Patients treated beyond progression P value
Nivolumab n (%) Placebo n (%)
N 109 37
Sex
 Male 78 (71.6) 30 (81.1) 0.29
 Female 31 (28.4) 7 (18.9)
Age (years)
 < 65 58 (53.2) 20 (54.1) 1.00
 ≥ 65 51 (46.8) 17 (45.9)
ECOG performance status score (eCRF source)
 0 38 (34.9) 15 (40.5) 0.56
 1 71 (65.1) 22 (59.5)
Recurrent
 No 58 (53.2) 23 (62.2) 0.44
 Yes 51 (46.8) 14 (37.8)
Histological type (Lauren classification)
 Intestinal type 43 (39.4) 18 (48.6) 0.25
 Diffuse type 29 (26.6) 12 (32.4)
 Others 8 (7.3) 0
 Unknown 29 (26.6) 7 (18.9)
Number of organs with metastases
 < 2 38 (34.9) 14 (37.8) 0.85
 ≥ 2 71 (65.1) 23 (62.2)
Number of prior regimens
 2 15 (13.8) 8 (21.6) 0.38
 3 48 (44.0) 12 (32.4)
 ≥ 4 46 (42.2) 17 (45.9)
PD-L1 expression
 ≥ 1% 7 (6.4) 1 (2.7) 0.85
 < 1% 38 (34.9) 13 (35.1)
 Missing 64 (58.7) 23 (62.2)
Diameters of target lesions (mm)
 n 92 31
 Median 57.6 51.0 0.93
Time to first progression (months)
 Median 1.58 1.48 0.18
 Mean 4.54 3.19 0.16
Poststudy treatment (pharmacotherapy)
 Yes 55 (50.5) 20 (54.1) 0.85
 Fluoropyrimidine 21 (19.3) 10 (27.0)
 Taxane 15 (13.8) 7 (18.9)
 Platinum 13 (11.9) 7 (18.9)
 Irinotecan 9 (8.3) 3 (8.1)
 Ramucirumab 26 (23.9) 7 (18.9)
 Immunotherapy 3 (2.8) 1 (2.7)
 Other targeted therapies 3 (2.8) 0
BOR
 CR 0 0 0.038
 PR 14 (12.8) 0
 SD 27 (24.8) 7 (18.9)
 PD 48 (44.0) 24 (64.9)
 NE 20 (18.3) 6 (16.2)
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but appearance of a new lesion (n = 31, Fig. 5b), and both 
a target lesion progression of ≥ 20% and a new lesion 
(n = 17, Fig. 5c). During TBP, some tumor shrinkage 
compared with the tumor size at the first event of PD was 
observed only in 7 of 41 (17%) patients with progression 
of target lesion by ≥ 20% regardless of appearance of a 
new lesion. On the contrary, 15 of 31 (48%) patients with 
lesion progression of < 20% in previously existing tumor 
lesions and new lesion emergence had some tumor shrink-
age during TBP.
In patients with the BOR of CR/PR (n = 8), SD (n = 9), 
and PD (n = 14) who experienced PD due to the appear-
ance of a new lesion without progression of target lesion 
by ≥ 20%, 6 (75%), 2 (22%), and 7 (50%) patients, respec-
tively, had some tumor shrinkage during TBP (Online 
Resource Figs. 4, 5, and 6).
Safety
No new TRAEs developed after the previously reported 
2-year follow-up [19]. In the nivolumab group, TRAEs 
of special interest were interstitial lung disease (n = 6 
[1.8%]), maculopapular rash (n = 5 [1.5%]), colitis (n = 2 
[0.6%]), hyperthyroidism (n = 2 [0.6%]), pneumonitis 
(n = 2 [0.6%]), acute hepatitis (n = 1 [0.3%]), autoim-
mune thyroiditis (n = 1 [0.3%]), hypopituitarism (n = 1 
[0.3%]), and thyroid disorder (n = 1 [0.3%]) at the 3-year 
follow-up. Maculopapular rash was observed in one 
patient of the placebo group (Online Resource Table 4).
Discussion
The 3-year follow-up of the ATT RAC TION-2 study con-
firmed that nivolumab consistently prolonged the OS com-
pared with placebo and was associated with numerically 
higher 3-year OS and PFS rates in patients with unresect-
able advanced or recurrent G/GEJ cancer after failure of 
≥ 2 prior chemotherapy regimens. A total of 15 patients 
in the nivolumab group and three patients in the placebo 
group survived longer than 3 years (two of the three 3-year 
survivors in the placebo group received nivolumab as sub-
sequent therapy). Noticeably, responders with PR or CR 
in the nivolumab group had a favorable 3-year survival 
rate, as high as 35.5%. Moreover, among the patients 
with SD and PD as their BOR, treatment with nivolumab 
resulted in relatively longer survival compared with pla-
cebo. Although the overall long-term survival rate was 
not satisfactory compared with that in melanoma and lung 
cancer, it is considered that nivolumab can contribute to 
prolongation of survival in some patients with advanced or 
recurrent G/GEJ regardless of the BOR [8, 15–18].
In renal cell carcinoma (CheckMate 025) [27] and 
head and neck cancer (CheckMate 141) [31], TBP with 
nivolumab had a survival benefit. However, as a limitation 
of these analyses, patients who received TBP might be in a 
Fig. 3  PPS in TBP patients after 
3 years of follow-up. Vertical 
marks on the curve indicate 
patients who were censored. CI 
confidence interval, HR hazard 
ratio, PD progressive disease, 
PPS postprogression survival, 
TBP treatment beyond progres-
sion
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Fig. 4  Subanalysis of PPS 
by BOR among TBP patients 
with CR + PR (a), SD (b), 
and PD (c). Vertical marks 
on the curve indicate patients 
who were censored. BOR best 
overall response, CI confidence 
interval, CR complete response, 
HR hazard ratio, PD progressive 
disease, PPS postprogression 
survival, PR partial response, 
SD stable disease, TBP treat-
ment beyond progression
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better condition compared with those who did not. Medi-
cal condition at initiation of pharmacotherapy influences 
its efficacy. Indeed, the demographics and background 
characteristics of patients in this study showed that the 
proportions of patients with poor prognostic factors, such 
as ECOG PS 1, number of metastatic organs ≥ 2, and large 
diameter of target lesions, were relatively lower in the TBP 
cohort compared with the non-TBP cohort. However, there 
were no remarkable differences in patient background at 
enrollment between the nivolumab and placebo groups 
in the TBP cohort (Table 1), while there were some dif-
ferences in the BOR before starting TBP. Among the 
TBP patients, PPS tended to be longer in the nivolumab 
group than in the placebo group (median 5.75 months vs 
4.50 months; HR 0.69), while PPS was similar between 
them among the non-TBP patients (median 2.27 months 
vs 2.23 months, respectively; HR 0.90). This subanalysis 
suggests the efficacy of TBP with nivolumab over pla-
cebo for unresectable advanced or recurrent G/GEJ cancer. 
However, the median duration of TBP with nivolumab was 
as short as 1.12 months, which means that TBP was dis-
continued due to a second PD at the first evaluation after 
initiating TBP in more than half of the patients. Thus, it 
is not clear which could provide better clinical outcomes, 
TBP with nivolumab or a switch to other pharmacother-
apies. The clinical decision for selecting optimal treat-
ments at the first event of PD with nivolumab is important 
for patients with advanced unresectable or recurrent G/
GEJ cancer who have small chances for further treatment. 
Thus, it is necessary to establish biomarkers for identify-
ing patients suitable for TBP with nivolumab.
Patients who received TBP after the first event of PD 
included patients with various BORs such as CR, PR, SD, 
and PD. The median (95% CI) PPS of responders in the 
nivolumab group was as long as 12.48 (10.05–21.78) months 
(Fig. 4a) with a relatively long median TBP duration of 
4.75 months. This median TBP duration appeared to be 
longer than the median PFS of irinotecan [32] and triflu-
ridine–tipiracil [33]. However, the extent of contribution 
of nivolumab during TBP toward a favorable PPS in these 
responders is not clear since the patients’ condition could 
be improved by response to nivolumab before starting 
TBP. Furthermore, the immunological status modified by 
nivolumab might have a good influence on the efficacy of 
subsequent chemotherapy. Although it is still unclear which 
is beneficial, i.e., TBP with nivolumab or switching to sub-
sequent chemotherapy after the first event of PD even for 
responders, responders might be candidates for TBP with 
nivolumab.
Unexpectedly, among TBP patients with the BOR of 
SD, the placebo group tended to have a longer PPS com-
pared with the nivolumab group. This observation could 
be attributed to the small sample size of TBP patients with 
the BOR of SD, particularly in the placebo group (only 
7 patients). Furthermore, it is speculated that patients with 
the BOR of SD in the placebo group had naturally indolent 
tumors, with a range of TBP duration with placebo from 
0 to 11.1 months, whereas some patients with SD in the 
nivolumab group might have had an originally aggressive 
tumor whose progression was suppressed by nivolumab. The 
criteria for SD range from shrinkage by < 30% to growth 
by < 20%, and some tumor shrinkage by < 30% within SD 
Fig. 5  Spider plot during TBP of patients who were evaluated for 
BOR in the nivolumab group, categorized by PD patterns, in patients 
with target lesion. Spider plot showing PD categorized by PD pat-
terns in TBP patients with target lesion progression of ≥ 20% with-
out new lesions (n = 24) (a), target lesion progression of < 20% with 
appearance of new lesions (n = 31) (b), and target lesion progression 
of ≥ 20% and appearance of new lesions (n = 17) (c). BOR best over-
all response, PD progressive disease, TBP treatment beyond progres-
sion
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represents the efficacy of nivolumab. In fact, in our previ-
ous report, patients achieving tumor shrinkage by 5–30% 
showed longer survival and a better HR than those with 
tumor growth by 5–20% [19]. Thus, among patients with the 
BOR of SD who received TBP, there might be some differ-
ences in tumor biology between the nivolumab and placebo 
groups, and there was a substantial variation in the response 
to nivolumab. These factors should be taken into considera-
tion when deciding TBP with nivolumab for patients with 
the BOR of SD.
Among TBP patients with the BOR of PD, the nivolumab 
group showed a relatively longer PPS compared with the 
placebo group (4.24 months vs 3.78 months; HR 0.70). In 
the nivolumab group, 10 of 14 1-year survivors with the 
BOR of PD received TBP (Fig. 2c). In contrast, among 
patients with the BOR of PD who did not receive TBP, there 
was no difference in PPS between the nivolumab group and 
the placebo group (Online Resource Fig. 7). These results 
suggest that TBP with nivolumab might have a survival 
benefit compared with placebo even for patients with the 
BOR of PD if the patient’s condition is preserved. However, 
this subgroup did not include patients experiencing rapid 
progression for which TBP was judged to be inappropriate 
by physicians. It should be noted that TBP with nivolumab 
should not be performed after rapid progression (not allowed 
in the protocol of the ATT RAC TION-2 study).
In some cases, conventional guidelines for response 
assessment do not work well for the evaluation of the tumor 
response to immunotherapy. Recently, a new guideline, iRE-
CIST, has been proposed specifically for immunotherapy 
[34]. In iRECIST, the appearance of a new lesion is not 
classified as PD but is recognized as a new evaluable or 
non-evaluable lesion that is added to pre-existing lesions for 
response assessment [34]. In this study, TBP was evaluated 
according to the PD pattern per RECIST (tumor progres-
sion of previously existing lesions and/or new lesion emer-
gence). Among 41 patients with progression of target lesion 
by ≥ 20% with or without new lesions, 7 (17%) patients had 
some tumor shrinkage during TBP. Although a common con-
sensus on the definition of pseudoprogression is still lacking 
[25, 35], the incidence of pseudoprogression is considered 
to be rare in solid tumors [36]. In contrast, many of the 
responders (8/10, 80%) experienced PD due to the appear-
ance of a new lesion without progression of existing target 
lesions by ≥ 20% and showed favorable clinical outcome in 
TBP with nivolumab. Among all patients (n = 72) evaluated 
with PD pattern regardless of BOR, 31 (44%) experienced 
PD due to the appearance of a new lesion without progres-
sion of target lesion by ≥ 20%. In these 31 patients, 15 (48%) 
had some tumor shrinkage associated with long duration of 
TBP. Thus, regardless of BOR, patients who experienced PD 
due to the appearance of a new lesion without progression 
of ≥ 20% in previously existing target lesions had a trend to 
have longer PPS with nivolumab than those who had other 
PD patterns. These results suggest that the immunological 
environment differs depending on the disease sites (pattern 
of PD) and that TBP with nivolumab might be effective in 
patients with lesion progression < 20% in previously existing 
target lesions and new lesion emergence. It is expected that 
future biomarker research based on these results will lead 
to finding biomarkers not only for identifying patients suit-
able for TBP with nivolumab but also for new combination 
therapy with other immunological drugs and/or molecular 
targeted agents.
This study has some limitations. This was a post hoc 
analysis of the TBP subsets with a small sample size. Infor-
mation on patient background characteristics at the start of 
TBP was not collected. Translational research for biomarkers 
predicting the efficacy of nivolumab in TBP patients will be 
required to confirm these observations.
Conclusions
The long-term efficacy of nivolumab was confirmed through-
out the 3-year follow-up period in the ATT RAC TION-2 
study, with no new safety signals. TBP with nivolumab 
showed a tendency to prolong PPS compared with placebo, 
and a survival benefit of TBP with nivolumab was sug-
gested. The clinical significance of TBP with nivolumab and 
biomarkers for selecting patients suitable for TBP should be 
verified in the near future.
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